Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03225963
Recruitment Status : Unknown
Verified July 2017 by Taichung Veterans General Hospital.
Recruitment status was:  Recruiting
First Posted : July 21, 2017
Last Update Posted : July 24, 2017
Sponsor:
Information provided by (Responsible Party):
Taichung Veterans General Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Condition or disease Intervention/treatment
Glioblastoma Multiforme Angiogenesis Radiation: Chemoradiation with temozolomide

Detailed Description:
Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
Actual Study Start Date : August 1, 2015
Estimated Primary Completion Date : July 31, 2018
Estimated Study Completion Date : July 31, 2018

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Response of bevacizumab therapy. [ Time Frame: 3 months after bevacizumab therapy ]
    Base on the image after bevacizumab therapy (after recurrence)


Biospecimen Retention:   Samples With DNA
DNA of peripheral mononulcear cells.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Obtain peripheral blood pre-chemotherapy, mid-chemoradition and post-chemoraidtion
Criteria

Inclusion Criteria:

  • Age older than 20 year old.
  • Glioblastoma patients who will receive chemoradiation treatment.

Exclusion Criteria:

  • None
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03225963


Contacts
Layout table for location contacts
Contact: Weir Chiang You, M.D. Ph.D. 886-4-23592525 ext 5602 bigjohnyou@vghtc.gov.tw
Contact: Hui Lin Yeh, M.D. 886-4-23592525 ext 5621 yehl@vghtc.gov.tw

Locations
Layout table for location information
Taiwan
Taichung Veterans General Hospital Recruiting
Taichung, Taiwan, 407
Contact: Weir Chiang You, M.D. PhD    886-4-23592525 ext 5602    bigjohnyou@vghtc.gov.tw   
Sponsors and Collaborators
Taichung Veterans General Hospital
Investigators
Layout table for investigator information
Study Chair: Weir Chiang You, M.D. Ph.D. The Institutional Review Board of Taichung Veterans General Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Taichung Veterans General Hospital
ClinicalTrials.gov Identifier: NCT03225963    
Other Study ID Numbers: CE15180B
First Posted: July 21, 2017    Key Record Dates
Last Update Posted: July 24, 2017
Last Verified: July 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Taichung Veterans General Hospital:
Glioblastoma
Bevacizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
 Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents